Kenvue (NYSE:KVUE) Price Target Cut to $21.00 by Analysts at UBS Group

Kenvue (NYSE:KVUE) had its price objective trimmed by UBS Group from $23.00 to $21.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other equities analysts have also issued reports on the company. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Barclays lowered their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Finally, Citigroup dropped their target price on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Kenvue Trading Up 2.2 %

Shares of KVUE opened at $20.23 on Friday. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm has a market cap of $38.79 billion, a price-to-earnings ratio of 38.17, a PEG ratio of 2.16 and a beta of 1.45. The firm has a 50 day moving average price of $21.61 and a 200-day moving average price of $21.93. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts forecast that Kenvue will post 1.05 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 4.05%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Institutional Investors Weigh In On Kenvue

Hedge funds have recently made changes to their positions in the company. Sequoia Financial Advisors LLC lifted its position in Kenvue by 18.7% during the fourth quarter. Sequoia Financial Advisors LLC now owns 29,309 shares of the company’s stock valued at $626,000 after buying an additional 4,619 shares during the period. Saturna Capital Corp lifted its position in Kenvue by 28.2% during the 4th quarter. Saturna Capital Corp now owns 1,711,024 shares of the company’s stock valued at $36,530,000 after acquiring an additional 376,164 shares during the period. Moors & Cabot Inc. lifted its position in Kenvue by 2.4% during the 4th quarter. Moors & Cabot Inc. now owns 184,528 shares of the company’s stock valued at $3,940,000 after acquiring an additional 4,327 shares during the period. King Luther Capital Management Corp boosted its stake in Kenvue by 286.5% during the fourth quarter. King Luther Capital Management Corp now owns 207,367 shares of the company’s stock worth $4,427,000 after acquiring an additional 153,715 shares in the last quarter. Finally, Citizens Financial Group Inc. RI purchased a new stake in Kenvue in the fourth quarter worth about $229,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.